Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $71.0 million.

  • Neurogene's Cash & Equivalents rose 656.13% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.0 million, marking a year-over-year increase of 656.13%. This contributed to the annual value of $136.6 million for FY2024, which is 784.29% down from last year.
  • Neurogene's Cash & Equivalents amounted to $71.0 million in Q3 2025, which was up 656.13% from $58.8 million recorded in Q2 2025.
  • Neurogene's 5-year Cash & Equivalents high stood at $150.1 million for Q1 2024, and its period low was $25.2 million during Q3 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $70.8 million (2025), whereas its average is $82.3 million.
  • Per our database at Business Quant, Neurogene's Cash & Equivalents skyrocketed by 32300.11% in 2024 and then tumbled by 5286.33% in 2025.
  • Over the past 3 years, Neurogene's Cash & Equivalents (Quarter) stood at $148.2 million in 2023, then dropped by 7.84% to $136.6 million in 2024, then tumbled by 48.01% to $71.0 million in 2025.
  • Its Cash & Equivalents stands at $71.0 million for Q3 2025, versus $58.8 million for Q2 2025 and $70.8 million for Q1 2025.